ICPT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 Nov 2023 @ 16:00):

Stats
Today's Volume	3.91M
Average Volume	2.05M
Market Cap	794.69M
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.43
ATR14	$0.410 (2.16%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-08	Akkaraju Srinivas	Sell	640 688	Common Stock
2023-11-08	Akkaraju Srinivas	Sell	8 111	Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 089	Option to Purchase Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 790	Option to Purchase Common Stock
2023-11-08	Akkaraju Srinivas	Sell	12 547	Option to Purchase Common Stock

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 1 646 020

Volume Correlation

Long: 0.26 (neutral)

Short: 0.00 (neutral)

Signal:(75.794) Neutral

Intercept Pharmaceuticals Correlation

10 Most Positive Correlations
LIQT	0.919
TREE	0.912
PIRS	0.9
PALT	0.896
HLMN	0.891
IPDN	0.888
VRME	0.888
IDCC	0.885
STX	0.883
LILA	0.883

10 Most Negative Correlations
TUEM	-0.876
AVIR	-0.849
DTSS	-0.843
GMII	-0.842
AHPI	-0.841
CFV	-0.841
JRJC	-0.841
AFYA	-0.832
GOEV	-0.831
APM	-0.824

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intercept Pharmaceuticals Correlation - Currency/Commodity

0.81
( strong )

-0.56
( weak negative )

0.64
( weak )

-0.57
( weak negative )

-0.31
( neutral )

Intercept Pharmaceuticals Financials

Annual	2022
Revenue:	$285.71M
Gross Profit:	$284.73M (99.66 %)
EPS:	$3.40

Q3	2023
Revenue:	$88.79M
Gross Profit:	$88.59M (99.78 %)
EPS:	$-0.0668

Q2	2023
Revenue:	$83.72M
Gross Profit:	$83.53M (99.78 %)
EPS:	$-0.140

Q1	2023
Revenue:	$67.96M
Gross Profit:	$67.74M (99.67 %)
EPS:	$-0.710

Financial Reports:

No articles found.

Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.